FDA rejects Ascendis Pharma drug
In a not-so-unexpected turn of events, the US Food and Drug Administration (FDA) has rejected drugmaker Ascendis Pharma’s TransCon PTH and its related device.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bad news from FDA slashes market value of Ascendis
For subscribers
FDA points out shortcomings in Ascendis application
For subscribers
FDA sets deadline for Ascendis Pharma drug decision
For subscribers